Search

Your search keyword '"Schiff, Eugene"' showing total 1,147 results

Search Constraints

Start Over You searched for: Author "Schiff, Eugene" Remove constraint Author: "Schiff, Eugene"
1,147 results on '"Schiff, Eugene"'

Search Results

1. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection

4. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection

5. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

6. Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1

8. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

11. Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study

14. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B

18. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid

20. Reply

21. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

22. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

23. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

27. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial

31. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma

32. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

33. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials

34. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

35. Peginterferon Alfa-2b orAlfa-2a with ribavirin for treatment of hepatitis C infection

40. Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis

42. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

44. Hepatitis C and alcohol

45. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. (Major Article)

Catalog

Books, media, physical & digital resources